Positive results of selinexor, bortezomib, and dexamethasone in myeloma patients who have received one to three prior lines of therapy
New data of the phase 3 Boston clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from 29 to 31 May 2020. This study evaluates weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in myeloma patients who have received one to three prior lines of therapy.